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Abstract
Background: Malignant transformation of endometriosis associated with episiotomy scar is a rare event, especially
histological type of clear cell adenocarcinoma. There are only three clear cell carcinoma in episiotomy scar reported,
no standard treatment established.
Case presentation: A 36-year-old woman presented with a two-month history of painless but puritic perineal
lump which she noticed was gradually enlarging. She had undergone surgical excision of a mass in the episiotomy
scar 9 year ago and resequently histological type of endometriosis. Physical examination revealed a 10 × 5 cm soft,
purple scar which is closely related to the apex of the episiotomy.We underwent a local excision of the mass for a
biopsy . The second surgery performed after one cycle of paclitaxel and cisplatin (TP) to permit clearance of tumor
while preserving normal vaginal function.Pathological result was clear cell adenocarcinoma. Two cycles of TP
adjuvant chemotherapy were administrated after surgery.
Conclusions: We report a case of primary clear cell carcinoma developing within a previous episiotomy scar in a
patient with a history of endometriosis, along with a review of the literature. Accumulation of management data on
these rare tumors and Long-term follow-up of such patients is therefore important.
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Background
Malignant transformation of endometriosis associated
with episiotomy scar is a rare event, especially histo-
logical type of clear cell adenocarcinoma. In 1990 Hitti
first described primary clear cell adenocarcinoma in a
perineal endometriosis. To the best of our knowledge,
there are only three case reports on record. We report a
case of primary clear cell Carcinoma developing within a
previous episiotomy scar in a patient with a history of
endometriosis, along with a review of the literature.
Case presentation
A 36-year-old woman presented with a two-month history
of painless but puritic perineal lump which she noticed
was gradually enlarging. The patient’s past gynecological
history included frequent vaginitis owing to bad health
habits and the lack of professional treatment. Because of
discomfort, the patient often scratched the vulva including
the lesion of the episiotomy scar for many years. In
addition, her past obstetric history was significant. She had
a history of a forceps delivery 20 years ago. The postopera-
tive recovery of perineal wound was slow. Several months
after delivery, she experienced cyclic perineal pain and
swelling of the episiotomy scar. Mifesterone and Medroxy-
progesterone acetate injectable suspension (DMPA) were
used and the pain was relieved. She had undergone surgical
excision of a mass in the episiotomy scar 9 year ago and
resequently histological type of endometriosis. DMPA was
administrated for one year and then mifesterone for half a
year. Medical treatment with Chinese traditional medicine
was prescribed after that.
Physical examination revealed a 10 × 5 cm soft, purple
scar which is closely related to the apex of the episiotomy.
Pelvic examination and trans-vaginal ultrasound did not
detect other signs of pelvic or extra-pelvic endometriosis.
We underwent a local excision of the mass for a biopsy
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(Fig. 1a and b). Microscopically, pathological result was
clear cell adenocarcinoma (Fig. 2c and d). Endometriotic
focus was seen at the side of the cacinous area (Fig. 2e).
We clearly noticed transitional dysplastic zone between
the endometriotic focus and the clear cell carcinoma
(Fig. 2f). The second surgery performed after one cycle of
paclitaxel and cisplatin (TP) to permit clearance of tumor
while preserving normal vaginal function. The patient
underwent radical vulvar excision with skin graft and in-
guinal lymphadenectomy. The pathologic result showed
the deep and lateral margins are clear. The patient was
discharged after 10 days of hospitalization without any
complication. Two cycles of TP adjuvant chemotherapy
were administrated after surgery. The patient has returned
to work at the time of manuscript preparation.
Discussion
Sampson first proposed three criteria to diagnosis malig-
nancy arising in endometriosis in 1925 [1]. The clinical
symptoms of malignancy of endometriosis were men-
strual irregularity, the enlargement of the mass, in-
creased pain, etc. There are no specific tumor markers
in malignant transformation of extraovarian lesions. J.
Cuisenier reported the level of CA125 is within normal
range in 44 % of patients with extraovarian lesions ver-
sus just 15.38 % of patients in ovarian endometriosis [2].
Patients with endometriosis were reported to be 3-folds
associated with clear cell carcinoma and endometroid
carcinoma. Because of the high risk and no typical clinical
tumor marker, patients those were verified as endometri-
osis in episiotomy scar should be followed up closely.
Endometrioid and clear cell carcinomas are a more
common histotype in endometriosis associated ovarian
carcinoma (EAOC) than in non-EAOC. The histotype of
malignancy occurring from extraovarian endometriosis
was reported as follows: endometrioid carcinoma be-
tween 75.9 and 69.1 %, clear cell carcinoma between
13.5 and 4.5 % [3]. Sara C reported 28 cases of malig-
nancy arising from abdominal wall scars, of which 22
were endometroid or clear cell carcinoma [4]. Among
four reported malignancies arising from episiotomy scars,
three were clear cell carcinoma [3, 5–7]. The presence of
a transitional dysplatic zone between benign endometri-
osis and cancer is one of the most important feature in
the microscopic appearance of a carcinoma arising from
endometriotic foci [8]. Approximately 36–42 % of endo-
metriosis associated cancers have this dysplatic zone [9].
The previous three cases of clear cell carcinoma arising
from episiotomy scar also reported the transitional zone.
The transitional zone was detected in our report. In
addition, similar to the present case, the microscopic or
macroscopic coexistence with endometriosis was reported
in the past three cases.
The best explanation of the pathogenesis of endomet-
riosis in episiotomy scar is transport theory. Transport
theory involves iatrogenic transplantation of the endo-
metrium to the surgical wound. Our patient had a lateral
episiotomy because of dystocia. This theory might ex-
plain the endometrial tissue can be transported to the
vulvar tissue during delivery. However, this theory can
not explain the rare cases of endometriosis in organs
such as the lung and kidney [10]. There are other theor-
ies such as lymphatic or haematogenic dissemination,
coelomic metaplasia and cell immunity change theory,
which are proposed to explain this.
Whether or not endometriosis in episiotomy scar is a
sign of its progression to carcinoma have a controversy.
The rare case of this clear cell carcinoma in previous
episiotomy scar may give evidence to tumor carcinogen-
esis in extraovarian endometriosis. The etiology of ma-
lignant transformation of endometriosis is not clear.
Several aspects were summarized as the cause of malig-
nant transformation of endometriosis. First, the genetic
mutation was proposed to be associated with the trans-
formation of endometriosis into carcinoma. Loss of het-
erozygosity at locus 10q23.3, mutation of the tumor
suppressor gene PTEN and P53 alteration was reported
to be relevated with the development of endometriosis
Fig. 1 a Perioperative photograph showing a 10 × 5 cm perineal mass arising from the episiotomy scar. b Cut surface of the tumor, pink-yellow in color
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associated cancer [11]. Mutations of ARIDIA was re-
ported more often in clear cell carcinoma [12]. David G.
Huntsman reported the Mutations of ARIDIA and the
loss of BAF250a expression, is an early event in the trans-
formation of endometriosis into cancer [13]. ARID1A
inactivation and PI3K/AKT pathway alterations may be
consistent to initiate carcinogenesis [14]. The detection of
gene mutation is difficult in clinical work, but these
research give us some potential therapeutic approach in
the future.
Secondly, hormone level has a role in the pathogenesis.
Hyperestrogenism was reported to be associated with the
development of endometrioid cancer and clear cell carcin-
oma [15]. Okamura K reported progesterone resistance
within endometriosis [11]. This can explain why the use of
DMPA for a long time in our case and the endometriosis
also developed into cancer. In addition to that, Endometri-
osis is associated with a local inflammatory reaction lead-
ing to cytokine release. Balkwill and Mantovany offer an
description of this link: If genetic damage is the ‘match
that lights a fire’ of cancer, some types of inflammation
may provide ‘the fuel that feeds the flames [16]. Cytokines
within the endometriosis microenvironment, such as IL-1
is associated with increasing the synthesis of prostaglandin
E2 (PGE2) which cause angiogenesis, proliferation, and in-
hibition of apoptosis similar to malignant mechanisms [17].
Table 1 summarize the previous reported cases arising
in episiotomy scar together with our case. A total of 4
cases of malignant transformation of episiotomy scar
endometriosis have been reported in previous literature.
Table 1 Summary of the carcinoma arising in episiotomy scar
Author Year Histology Treatment The follow up
Hitti IF [5] 1990 Clear cell carcinoma radiotherapy and chemotherapy dead at 30 months
Todd RW [6] 2000 Clear cell carcinoma radiotherapy and chemotherapy remission at 6 months
Chene G [3] 2007 Serous papillary
Cystadenocarcinoma
Complementary radiotherapy and chemotherapy-Radical and
complete Excision
remission at 6 months
Yong-Soon
Kwon [7]
2008 Clear cell carcinoma Radical excision no evidence of disease to
10 months
Current report 2014 Clear cell carcinoma radical resection and chemotherapy no evidence of disease to
6 months
Fig 2 Microscopic images: c clear cell adenocarcinoma: marked cellular pleomorphism, clear cytoplasm, nuclei show pleomorphism. d Characteristic
hobnail cells are noted in our case. e Endometriosis: cystic dilated endometrial glands in dense stroma. f Transitional zone revealing clear cell carcinoma
arising from the endometriotic focus
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Table one list several reports with different treatments
of these disease. The radical excision was administrated
along with or no adjuvant therapy. Because the tumor
size of our patient is big and the histological type was
clear cell carcinoma, chemotherapy was administrated in
our patient and the recovery of the patient was well till
now, but long-term follow-up result of the efficacy of ad-
juvant therapy is uncertain.
Conclusions
We report a case of clear cell carcinoma arising from
episiotomy scar. There are only three clear cell carcinoma
in episiotomy scar reported, no standard treatment estab-
lished. Accumulation of management data on these rare
tumors and Long-term follow-up of such patients is there-
fore important.
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